$3M deal: Trevena signs licensing agreement with South Korean biopharm firm

Trevena Inc. entered into an an exclusive license agreement covering the development and commercialization rights for its new drug candidate oliceridine, an experimental pain relief medicine, in South Korea. Under the terms of the agreement, Pharmbio Korea Inc. will make a $3 million upfront payment to Trevena (NASDAQ: TRVN). Trevena of Chesterbrook, Pa., will also be eligible for undisclosed commercialization milestone payments and tiered royalties on product sales ranging from high single digits…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news